Hot Topics

CEI PEP/PrEP Line: 1-866-637-2342

Posted September 2014

CEI PEP/PrEP Line: 1-866-637-2342

The New York State Department of Health AIDS Institute in collaboration with the CEI program at Mt. Sinai Institute for Advanced Medicine offers this hotline for providers needing consultation with an HIV Specialist regarding the pre-exposure and post-exposure management of HIV. The CEI PEP/PrEP Line operates 24 hours a day, 7 days a week. Clinicians will assist callers in assessing of risk of the exposure, discuss the most recent New York State pre- and post-exposure prophylaxis guidelines, and review specific treatment and follow-up options.

CEI PEP/PrEP Line:    1-866-637-2342
Hours:                            24 hours/7 days a week

For more information about CEI and the other disease specific services of the CEI Line, please visit

CEI PEP/PrEP Line Poster

To order copies of this poster, please email Terri Wilder at:


^ Return to Top

Healthcare Stories Project: Activity 2 Materials

Posted January 2015

Materials are now available for Activity 2 of the Healthcare Stories Project, “How is Today’s Visit Going?,” including a poster, instructional guide, and activity worksheets. This installment is the second in a three-part initiative to add a critically important dimension to quality of care programs across New York State through the engagement of patients in their care experience, and the enhancement of consumer involvement at the programmatic level.

Activity two helps healthcare organizations understand what each part of a medical visit is like for healthcare users. This activity will enable healthcare staff to learn how to analyze information healthcare users share about their experiences, and apply this learning to develop quality improvement projects.

For more information, please click here.


^ Return to Top

Merck Discontinues Victrelis Voluntarily in USA

Posted January 2015

Merck has decided to voluntarily discontinue the manufacture and distribution of bocepravir (VICTRELIS) in the United States by December 2015.

To download the press release, please visit

For more information, please visit the FDA website at


^ Return to Top

HIV Training NY: Full Slate of Trainings Through February

Posted January 2015

New York State Department of Health AIDS Institute

HIV Training NY

To register for any course, click on the appropriate registration link and enter your account log-in information. If you do not have an account with, you will need to sign up for one prior to registering for a course. For registration assistance, please contact the NYSDOH AIDS Institute’s HIV Education and Training Program at (518) 474-3045.

For more information, please visit at


^ Return to Top

NQC e-Newsletter | Sign up for the TQL! | Jan 2015

Posted January 2015

Hopefully you all enjoyed the holiday season and feel invigorated to continue our work in ending the AIDS epidemic. This month, NQC profiles St. Luke’s University AIDS Service Center because of their outstanding work in reducing their viral load rates. Each month, we try to bring you a profile of a grantee that has made an impact in AIDS care to provide you with new ideas. We hope you find this month’s profile valuable and adds to your understanding of how to improve viral load suppression rates.

I encourage you to apply to the Training of Quality Leaders (TQL) Program being held from March 31 through April 2, which will be held in Chicago, IL. Very soon, the 2015 Quality of Care Award and its application process will be announced. NQC will make sure that we do our best to meet the needs of all Ryan White Program grantees, so Join Us!

Tell us how NQC has helped you | Submit Your Testimony

NQC e-Newsletter

For more information, please visit


^ Return to Top

NYS Clinical Education: New CME Courses and Mobile CME Support

Posted January 2015

New CME Courses
The Clinical Education Initiative is pleased to announce the availability of three new CME courses. All courses are free and can be taken online at any time.

Please visit today to sign-up for these training opportunities.

Mobile CME Course Support
CEI continues to expand support for CME courses on mobile devices. Currently we offer twelve courses on mobile devices:

Please use your mobile device to visit today to access these training opportunities.

For more information, please visit


^ Return to Top

NYC Health: Health Department Launches New PrEP & PEP Campaign: New Ways to Prevent HIV

Posted January 2015

New PrEP & PEP Detailing Kit to Reach 600 Practices Citywide

Health Department Issues Health Alert to Providers Showing Benefits and Guidelines of PEP

The Health Department today launched a new outreach campaign, PrEP & PEP: New Ways to Prevent HIV, at The Oval Center at Montefiore Medical Center to provide primary care and infectious disease practices with resources to support pre-exposure and post-exposure prophylaxis (PrEP and PEP). Each year, approximately 3,000 New Yorkers are newly diagnosed with HIV. PrEP and PEP are highly effective in preventing HIV when taken as directed. PrEP is a pill taken daily to prevent HIV infection when used in combination with other risk reduction strategies, while PEP is a combination of pills taken daily for 28 days to prevent HIV infection immediately after a high-risk exposure to HIV.

Read the press release

Learn more about PrEP & PEP


^ Return to Top

NYC Health Alert Network: Emergency Post-Exposure Prophylaxis Can Prevent HIV Infection

Posted January 2015

Click here to download the NYC Department of Health and Mental Hygiene Health Alert #3 entitled Emergency Post-Exposure Prophylaxis Can Prevent HIV Infection


^ Return to Top

Governor Cuomo Announces Proposed Regulations to Provide Medicaid Coverage for Transgender Care and Services

Posted December 2014

Governor Andrew M. Cuomo on December 17, 2014 announced new regulations to include transgender health care services under New York State’s Medicaid program (PDF). The proposed regulations provide treatment for hormone therapy and gender reassignment surgery.

New York has always been a progressive leader and ensuring that all New Yorkers – regardless of gender identity – are treated fairly will continue this legacy,” Governor Cuomo said. “This new regulation will guarantee transgender New Yorkers access to Medicaid-funded care, which is critical to safeguarding the principle of equal treatment. I am proud that the State is taking this step and continuing to lead the fight on transgender rights.”

‘This modernization of our Medicaid payment coverage brings New York State in alignment with Medicare policy and improves the quality of life for New Yorkers whose gender identity is not the gender with which they were born.’
– Acting Health Commissioner Howard Zucker, M.D., J.D.

Under the proposed regulations, hormone therapy and gender reassignment surgery would be covered for persons who have referrals from medical professionals. Surgery would be covered for individuals who are a minimum age of 18 or 21 years old, depending on specific circumstances.

Referring medical professionals will have to document that a patient has persistent gender dysphoria, has received appropriate hormone therapy a minimum of one year, has lived a minimum of one year in the gender role consistent with the person’s gender identity and has received mental health counseling.

“Ensuring the equal treatment of all New Yorkers has been and continues to be a central focus of Governor Cuomo’s administration,” said Alphonso B. David, Deputy Secretary and Counsel for Civil Rights. “As the new regulation makes clear, transgender New Yorkers are no exception to this theme. With this regulatory change, these New Yorkers will be treated equally with respect to access to Medicaid-funded medical care.”

“Medical evidence supports gender reassignment surgery as a safe and effective treatment for gender dysphoria,” said acting Health Commissioner Howard Zucker, M.D., J.D. “This modernization of our Medicaid payment coverage brings New York State in alignment with Medicare policy and improves the quality of life for New Yorkers whose gender identity is not the gender with which they were born.”
New York will join California, Massachusetts, Oregon, Vermont, and Washington D.C., which cover transgender health care through their Medicaid programs. In May, the federal government also ended its decades-long exclusion of coverage for certain services related to gender transition under Medicare.

The introduction of this Medicaid regulation follows last week’s announcement that New York State law requires private health insurance companies to cover transgender health care on the same terms as other care. It also follows New York State’s revisions to its birth certificate policy for transgender people. Pursuant to that policy, corrected birth certificates are issued when a licensed medical provider states that a transgender individual has received appropriate clinical treatment.

The public will have 45 days to comment on the proposed regulation.

For more information, please visit


^ Return to Top

Medicaid Update: December

Posted December 2014

Dear Medicaid Provider,

The Office of Health Insurance Programs of the New York State Department of Health has approved the release of the December 2014 Medicaid Update.

Please click the link below to download the current edition. (PDF)

To see a list of all of the 2014 DOH Medicaid Updates, please visit


^ Return to Top

HIV Quality of Care Advisory Committee Meeting: December 11, 2014

Posted December 2014

Presentations from the December 11, 2014 HIV Quality of Care Advisory Committee meeting are now available.

Please click here to view the presentations.


^ Return to Top

What Were New Yorkers Viewing on in 2014?

Posted December 2014

The following pages were most viewed by New Yorkers in 2014:

  1. HIV Prophylaxis for Victims of Sexual Assault
  2. HIV Testing During Pregnancy and at Delivery
  3. Immune Reconstitution Inflammatory Syndrome (IRIS) in HIV-Infected Patients
  4. HIV and Syphilis
  5. Antiretroviral Therapy
  6. Diagnostic, Monitoring, and Resistance Laboratory Tests for HIV
  7. Primary Care Approach to the HIV-Infected Patient
  8. HIV Prophylaxis Following Non-Occupational Exposure
  9. HIV Prophylaxis Following Occupational Exposure

And the #1 most-viewed guideline by New Yorkers in 2014:

  1. Click here to view the most-downloaded guideline.


^ Return to Top

hivguidelines and Medscape: HIV in Older Adults: Commentary

Updated December 2014

Every few months Medscape features a New York State Department of Health AIDS Institute guideline along with commentary written by clinicians who work with the HIV Clinical Guidelines Program.

The most recent featured guideline is HIV in Older Adults: A Quick Reference Guide for HIV Primary Care Clinicians with commentary written by Dr Joseph P McGowan.

To view the commentary on Medscape, please click on the following link:

To see the full series of hivguidelines that have posted on Medscape so far, please visit the Medscape website at:

hivguidelines and Medscape Archives


^ Return to Top

HEALTHQUAL International: December 18

Posted December 2014

HEALTHQUAL is pleased to announce the publication of Improving rates of cotrimoxazole prophylaxis in resource-limited settings: implementation of a quality improvement approach in the current issue (Volume 26, Number 6) of the International Journal for Quality in Health Care.

This article describes application of quality improvement methods in four countries to monitor and improve administration of cotrimoxazole prophylaxis to advance health outcomes in adults living with HIV/AIDS in low- and middle-income countries.

Click here to read more

HEALTHQUAL Quality Management Development Program

HEALTHQUAL Quality Management Development Program

December 8-12, 2014: HEALTHQUAL hosted 45 delegates from 8 countries for a week-long intensive educational and peer learning opportunity focused on capacity building for national quality management programs. Participants from Haiti, Mozambique, Uganda, Rwanda, Papua New Guinea, Zambia, Zimbabwe and Ethiopia visited long-standing clinical quality management programs in New York City, met with government and institutional leadership and attended targeted meetings focused on learning objectives spanning leadership, patient involvement, patient safety, performance measurement, coaching and mentoring, and quality management planning, among others.

Learn more about the Quality Management Development Program

For more information, please visit


^ Return to Top

CDC's Division of HIV/AIDS Prevention: Funding Opportunity Announcement (FOA)

Posted January 2015

Enhancing HIV Prevention Communication and Mobilization Efforts Through Strategic Partnerships

The Centers for Disease Control and Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Division of HIV/AIDS Prevention, Prevention Communication Branch (PCB) is pleased to announce the publication of Funding Opportunity Announcement (FOA) The application deadline is March 23, 2015.

The purpose of this FOA is (1) to support the dissemination of Act Against AIDS (AAA) campaign materials, messaging and other CDC resources that support HIV prevention and (2) to implement national engagement efforts focusing on HIV prevention and awareness. Successful candidates will demonstrate ability to leverage existing organizational structures, networks, and communication platforms to disseminate AAA campaign materials and other CDC resources using a variety of channels including publications, meetings, conferences, media (traditional, digital, social) and other mechanisms.

With the scientific advances that have occurred in HIV prevention during recent years, this funding opportunity comes during an exciting time to change the tide of HIV in the country. Partnerships funded under this FOA will support CDC’s continued efforts to implement and sustain quality, high impact, HIV prevention in the United States and its territories.

CDC is hosting two pre-application technical assistance webinars for organizations interested in learning more about PS15-1505. These webinars are open to all eligible applicants, and participants have the option to submit questions to CDC at prior to each webinar. Please see the schedule and registration information for each webinar below:

PS15-1505 FOA Technical Assistance Webinar #1

PS15-1505 FOA Technical Assistance Webinar #2

To learn more about the eligibility, scope and requirements for PS15-1505, please visit


^ Return to Top

FDA Press Releases: December

Posted December 2014

FDA Commissioner Margaret A. Hamburg’s statement on FDA’s blood donor deferral policy for men who have sex with men
12/23/2014 01:00 PM EST

The U.S. Food and Drug Administration is a science-based regulatory agency that works to protect and promote the public health. In this role, it is our responsibility to regulate the blood supply and to help ensure its continued safety for the patients who receive these life-saving products.

FDA approves Viekira Pak to treat hepatitis C

The U.S. Food and Drug Administration today approved Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets co-packaged with dasabuvir tablets) to treat patients with chronic hepatitis C virus (HCV) genotype 1 infection, including those with a type of advanced liver disease called cirrhosis.

Approval of STRIBILD efficacy supplement
12/17/2014 05:39 PM EST

On December 17, 2014, the Indications and Usage section of the STRIBILD (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir 300mg) label was updated to include patients who are virologically-suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure in order to replace their current regimen. Patients should have no known substitutions associated with resistance to the individual components of STRIBILD.

FDA grants CLIA waiver expanding the availability of rapid screening test for syphilis
12/15/2014 12:10 PM EST

The U.S. Food and Drug Administration today announced that it granted the first-ever waiver, under certain laboratory regulations, for a rapid screening test for syphilis, which will allow the Syphilis Health Check test to be used in a greater variety of healthcare settings.

FDA approves Gardasil 9 for prevention of certain cancers caused by five additional types of HPV
12/10/2014 01:39 PM EST

The U.S. Food and Drug Administration today approved Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) for the prevention of certain diseases caused by nine types of Human Papillomavirus (HPV). Covering nine HPV types, five more HPV types than Gardasil (previously approved by the FDA), Gardasil 9 has the potential to prevent approximately 90 percent of cervical, vulvar, vaginal and anal cancers.

For more information, please visit the FDA website at


^ Return to Top

Quick News Update from OMD AIDS Institute: December 15

Posted December 2014

OMD SCREENSHOT – December 15, 2014

Here is important information from the Office of the Medical Director (OMD) AIDS Institute:

  • The final report from the September 11 HIV Quality of Care Clinical and Consumer Advisory Committee Joint Meeting is available here.
  • 2014 CDC Recommendations for HIV Prevention with Adults and Adolescents with HIV in the United States are available here. Companion summaries for clinical providers, nonclinical providers, and health departments and HIV planning groups are also available. Practical decision support tools, provider and patient fact sheets, and training materials have been posted on the CDC’s website.
  • FDA grants CLIA waiver for Alere Determine HIV – 1/2 Ag/Ab Combo Test
  • The NYCDOHMH HIV Surveillance Annual Report, 2013 is available here.
  • For a clinical inquiry regarding your patient with an STD, HIV, HCV, or those in need of PEP or PrEP call the Clinical Education Initiative at 1-866-637-2342


^ Return to Top

NYSDOH Dear Colleague Letter: Indeterminate Results on the HIV Western Blot

Posted November 2014

Please click here to download and view a Dear Colleague Letter from the AIDS Institute regarding indeterminate results on the HIV Western blot (WB) for New York State residents and providers.


^ Return to Top

New York City Health Alert: Update on Invasive Meningococcal Disease in Men Who Have Sex With Men

Posted September 2012; updated September 2014

September 5, 2014: NYC 2014 Health Alert #28: Update on Invasive Meningococcal Disease in Men Who Have Sex With Men (PDF 78.1 KB)

Since August 24, 2014, the New York City Department of Health and Mental Hygiene (NYC DOHMH) has identified three cases of invasive meningococcal disease (IMD) requiring hospitalization in intensive care units. A fourth case of IMD was identified in late June 2004. None of the patients has died.

All four cases were HIV-infected men who have sex with men (MSM), and the infections represent an apparent reemergence of IMD from the 2010-2013 outbreak that killed seven people.

As part of the ongoing effort to prevent further emergence of IMD, the New York State Department of Health and NYC DOHMH continue to recommend meningococcal vaccination for the following groups at highest risk for IMD:

  • All HIV-infected MSM who reside in New York City
  • MSM, regardless of HIV status, who reside outside of New York City but have engaged in the following risk behaviors when traveling to New York City: having regular close or intimate sexual contact with men met through an online website, digital application (“app”), or at a bar or party

Although a large number of people have received one dose of meningococcal vaccine, some HIV-infected persons have not received their second dose. HIV-infected patients who have not received their second dose should be contacted to return to the office for completion of vaccination. HIV-infected men who have sex with men should receive two doses of meningococcal conjugate vaccine, administered at least 8 weeks apart and no less than 6 weeks.

Providers should be aware of early clinical and laboratory findings that might indicate meningococcal septicemia, particularly in HIV-infected men MSM. Of the four cases among MSM that occurred in 2014, two of the individuals received two doses of meningococcal vaccine.

Previous IMD-Related Health Advisories and Alerts:

July 18, 2014: NYC 2014 Health Alert #15: Update on Invasive Meningococcal Disease in Men Who Have Sex With Men (PDF 52.5 KB)

August 14, 2013: NYC 2013 Health Alert #31: Update on Invasive Meningococcal Disease in Men Who Have Sex With Men (PDF 82.1 KB)

March 21, 2013: NYS 2013 Health Advisory Update #1: Expanded Outbreak Response Meningococcal Vaccine Recommendations for Men Who Have Sex With Men (PDF 126 KB)

March 6, 2013: NYC 2013 Health Alert #5: UPDATE: Invasive Meningococcal Disease in Men Who Have Sex With Men, Expanded Vaccine Recommendations (PDF 83.9 KB)

November 29, 2012: NYC 2012 Health Alert #36: UPDATE: Invasive Meningococcal Disease in Men Who Have Sex With Men (PDF 162 KB)

October 22, 2012: NYC 2012 Health Alert #30: UPDATE: Invasive Meningococcal Disease in Men Who Have Sex With Men (PDF 75.5 KB)

October 4, 2012: NYS 2012 Health Advisory/NYC 2012 Health Alert #28: UPDATE: Meningococcal Vaccine Recommendations for HIV-Infected Men Who Have Sex With Men (PDF 107 KB)

September 27, 2012: NYC 2012 Health Alert #27: Invasive Meningococcal Disease in Men Who Have Sex With Men (PDF 134 KB)

More Information:

Health Department Clinic Locations

If you think you might be at risk, please read the patient fact sheet (PDF)

See the related Frequently Asked Questions on Invasive Meningococcal Disease (PDF)

Meningitis Information for Health Care Providers

March 22, 2013: Centers for Disease Control and Prevention. Prevention and Control of Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep 2013;62(RR-2):1-22.

January 4, 2013: Notes from the Field: Serogroup C Invasive Meningococcal Disease Among Men Who Have Sex With Men — New York City, 2010–2012, Morb Mortal Wkly Rep 2013;61(51);1048.


^ Return to Top

Ending the Epidemic Regional Listening Forums Invitation

Posted October 2014

On June 29, 2014, Governor Cuomo announced a three-point plan to end AIDS as an epidemic in New York State. The goal of the initiative is to decrease new HIV infections to the point where, by 2020, the number of persons living with HIV in New York State will be reduced for the first time. To accomplish this goal the NYSDOH AIDS Institute will engage in strategies that are necessary to reduce the number of new HIV infections to just 750 by 2020.

We would like to invite you to participate in an AIDS Institute Regional Listening Forum that will take place at various locations throughout the State. These forums are intended to advise the Governor’s Task Force for Ending the Epidemic and achieve the goals set out in the three-point plan. The Listening Forums are intended to achieve the following:

  • Provide a forum for input and recommendations regarding the Governor’s three-point plan for Ending the Epidemic by reducing new HIV infections and improving the health of all HIV-infected New Yorkers.
  • Advise the Governor’s Task Force Committees, charged with developing recommendations to:
    • Identify persons with HIV who remain undiagnosed and link them to health care;
    • Increase access to Pre-Exposure Prophylaxis (PrEP) for high-risk persons to keep them HIV negative;
    • Support access to care and treatment in order to maximize viral load suppression;
    • Promote linkage and retention in care to achieve viral load suppression, decrease HIV transmission and promote the highest quality of life; and,
    • Ensure person-centered, culturally and linguistically appropriate prevention and health care services are available.

The Ending the Epidemic Task Force is comprised of key stakeholders representing government, private industry, consumers, and community leaders who are expert in the field of HIV and AIDS. The Task Force will meet on five occasions in 2014 and 2015 in Albany and New York City. The Task Force is supported by the Department’s AIDS Institute. The initial meeting was held October 14, 2014 from 10:30 a.m. to 5:00 p.m. in Troy, New York. The webcast of the first meeting is available at:

If you are willing to participate in this Listening Forum, please confirm your attendance by completing the RSVP form at this link: If you are unable to access the link, please call (518) 474-5577 no later than three days prior to the session. We are also looking to you to share this invitation with community members in your region. You may forward this email invitation to others or upload to your website or social media platform so that they have the RSVP, Recommendation Form and Ending the Epidemic website

If you and/or your colleagues are unable to attend, please use the Recommendation Form link: to submit recommendations ahead of the meeting. If you are unable to access the link, please send a hard copy to: NYSDOH AIDS Institute, Office of Planning & Community Affairs, Attn. June Kearney, ESP, Corning Tower Room 485, Albany, NY 12237. Should you have any questions, please submit them to We look forward to hearing from you regarding how we can address this critically important initiative of Ending the Epidemic in New York State.


^ Return to Top

Updates to DHHS Adult and Adolescent Opportunistic Infections Guidelines Released

Posted November 2014

Updates to the DHHS Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents were released on October 28, 2014. For a summary of the major updates, please see What’s New in the Guidelines.


^ Return to Top

Multi-Part Blog Series About State Health Department PrEP Education and Access Initiatives

Posted September 2014

As part of the continued focus on “Raising the Bars,” NASTAD is launching a new multi-part blog series about state health department pre-exposure prophylaxis (PrEP) education and access initiatives. This blog series will examine three states’ models for expanding PrEP programming.

  • New York: highlights a six step plan for creating an innovative, yet aggressive harm-reduction plan to end the AIDS epidemic by 2020 focused on utilization of PrEP for non-condom users and promotion of Treatment as Prevention (TasP) for all infected individuals.
  • Massachusetts (October): will share their involvement with local community health centers (CHCs) and advocacy community to move clinical research into authentic program implementation by creating unique education and access programs for each CHC’s diverse populations.
  • Washington (November): will showcase their unique PrEP medication access program modeled after the state’s AIDS Drug Assistance Program (ADAP) using state funds, ensuring communities in need can get the medication for free.

Additional NASTAD Resources:

Please contact Christopher Cannon if you have PrEP questions or want technical assistance.


^ Return to Top

NYSDOH Dear Colleague Letter: Opioid Overdose

Posted September 2014

Please click here to download and view a Dear Colleague Letter from the AIDS Institute regarding the New York State Opioid Overdose Prevention Program.


^ Return to Top

2014 New Developments in HIV Clinical Guidelines: What Non-Clinicians Should Know to Improve Patient Care and Coordination

Posted August 2014

2014 New Developments in HIV Clinical Guidelines: What Non-Clinicians Should Know to Improve Patient Care and Coordination

This series of one-hour webinars explores the latest HIV clinical guidelines with an emphasis on the specific knowledge that non-clinical providers should have and the actions they can take to support positive health outcomes for clients. Each monthly webinar features an engaging discussion with a leading physician who served on the NYSDOH AIDS Institute Clinical Guidelines Committee that developed the respective guideline.

September’s Topic: Acute HIV Infection

September 23, 2014
10:00 am – 11:00 am ET

Guest Presenter: Samuel T Merrick, MD, Associate Professor of Clinical Medicine, New York Presbyterian Hospital and Weill Cornell Medical Center; Medical Director, Center for Special Studies, Glenn Bernbaum Unit, NY Presbyterian Hospital Weill Cornell Medical Center; Medical Director, David E Rogers Unit, Judith Peabody Wellness Center

Register Here:

Click here, to download a promotional flyer with details.

You can also access an archived clinical guideline webinar (May 2014) — Pre-Exposure Prophylaxis (PrEP) Guidance — to view at your convenience. Guest Presenter: Demetre C Daskalakis, MD, Medical Director of Ambulatory HIV Services, Mount Sinai Comprehensive Health Program-Downtown.

Register Here:

For more information, please visit:


^ Return to Top

New York State HIV/AIDS Surveillance Annual Report

Posted August 2014

“The New York State HIV/AIDS Surveillance Annual Report” for Cases Diagnosed Through December 2012 has now been posted to the NYSDOH web site at the link below.


^ Return to Top

Cases on the Web: Drug Interactions with HCV DAAS

Posted August 2014

Drug Interactions With Hepatitis C Virus Direct-Acting Antivirals
John J. Faragon, PharmD, BCPS

The availability of direct-acting antiviral (DAA) drugs simeprevir, a nonstructural protein 4/5A (NS4/5A) hepatitis C virus (HCV) protease inhibitor, and sofosbuvir, a nonstructural protein 5B (NS5B) polymerase inhibitor in the management of HCV infection has led to dramatic increases in sustained virologic response (SVR) among patients receiving treatment with these drugs. Although these new HCV DAAs have improved response rates, their use may result in unexpected drug interactions with primary care medications and many HIV antiretroviral drugs. However, the risk of drug interactions with the new DAAs is likely to be lower than with earlier DAAs boceprevir and telaprevir.

On completion of this activity, the learner will be able to:

  • Describe the effects of HCV DAAs on cytochrome P450 and other systems involved with drug metabolism
  • Using patient cases, delineate strategies for preventing and managing interactions between HCV DAAs, primary care medications, and HIV medications
  • Identify reputable sources of information about drug interactions between HCV DAAs, HIV antiretroviral drugs, and common primary care medications

Visit to start learning from this new COW activity!


^ Return to Top

Dear Colleague Letter: Role of pre-exposure prophylaxis (PrEP) to prevent new HIV cases

Posted July 2014

Dear Colleague Letter Outlines Role of PrEP for HIV-Negative Individuals to Prevent New HIV Cases

Attached please find a Letter from Dan O’Connell, Director, AIDS Institute, that describes the role that pre-exposure prophylaxis for HIV (or PrEP) plays in the Governor’s three point plan to “bend the curve” on the AIDS epidemic. The letter outlines actions that can be taken by clinical and non-clinical providers to expand access to this important HIV prevention intervention.

Please feel free to share this letter with others in your organization and community.


^ Return to Top

Governor Cuomo Announces Plan to End the AIDS Epidemic in New York State

Posted June 2014; updated July 2014

Three-pronged Plan Focuses on Improved HIV Testing, Preventing the Spread of the Disease, and Better Treatment for People Who Have It

Governor Andrew M. Cuomo announced a three-point plan to “bend the curve” and decrease new HIV infections to the point where the number of people living with HIV in New York State is reduced for the first time. The end of the AIDS epidemic in New York will occur when the total number of new HIV infections has fallen below the number of HIV-related deaths.

The “Bending the Curve” three-point program includes:

  1. Identifying persons with HIV who remain undiagnosed and linking them to health care;
  2. Linking and retaining persons diagnosed with HIV to health care and getting them on anti-HIV therapy to maximize HIV virus suppression so they remain healthy and prevent further transmission; and
  3. Providing access to Pre-Exposure Prophylaxis (PrEP) for high-risk persons to keep them HIV negative.

To read the full announcement, please visit

Please click here to download a letter to Governor Cuomo from Michel Sidibe of UNAIDS expressing his support and interest in Governor Cuomo’s recent plan to end the AIDS epidemic in New York State by 2020.


^ Return to Top

PrEP/PEP Voluntary Directory

Posted July 2014

PrEP/PEP Voluntary Directory

To increase access to PrEP and PEP, the AIDS Institute is compiling a list of providers who prescribe PrEP/PEP for a voluntary directory. Please click here to access eight short questions to register as a provider.


^ Return to Top

CDC Recommendations: Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations

Posted June 2014

The CDC has released updated HIV testing recommendations. For resources for all FDA-approved diagnostic HIV tests for use in moderate and high complexity laboratories, please visit:


^ Return to Top

CDC Guidelines: PrEP Guidelines for the Prevention of HIV Infection

Posted May 2014

On Wednesday May 14, 2014, the Centers of Disease Control and Prevention (CDC) released guidelines to help providers identify potential candidates for the use of daily pre-exposure prophylaxis (PrEP) for the prevention of HIV infection. In January 2014, the New York State Department of Health AIDS Institute also released its own guidance document on PrEP.

For the CDC PrEP documents, see:

For the New York State Department of Health AIDS Institute PrEP guidance document, see Guidance for the Use of Pre-Exposure Prophylaxis (PrEP) to Prevent HIV Transmission.


^ Return to Top

What Support Services Providers Should Know About PrEP

Posted May 2014

From the New York State Department of Health AIDS Institute’s Improving Health Outcomes Series:

What Support Services Providers Should Know About PrEP (PDF 142 KB)


^ Return to Top

amfAR Fact Sheet: WHO Guidelines for the Screening, Care, and Treatment of Persons with Hepatitis C Infection

Posted July 2014

An estimated 150–180 million people are infected with hepatitis C globally; however, available hepatitis C treatments are complex and/or expensive, and many governments currently do not cover the costs of treatment. In April 2014, the World Health Organization published its first guidelines on screening, care, and treatment of hepatitis C infection to help government officials and healthcare providers in resource-limited settings establish effective programs to care for individuals infected with the virus.

The following fact sheet briefly summarizes the guidelines’ major recommendations, including who should be offered screenings for hepatitis C infection, how to monitor and reduce liver damage in those who test positive, and how to treat patients co-infected with HIV.

Please click here to download the fact sheet.


^ Return to Top

SAMHSA Update: 2 Publications To Help Clinicians Address Viral Hepatitis

Posted June 2014

Addressing Viral Hepatitis in People With Substance Use Disorders

Get an overview of viral hepatitis and information on screening, evaluation, treatment, side effects management, and potential interactions among medications used to treat chronic hepatitis, as well as medications used in the treatment of behavioral health disorders.

Get KAP Keys for Clinicians

Are You a Clinical Administrator?

Get succinct, easily accessible information that behavioral health clinicians can refer to when working with clients who have or may have hepatitis. The guide includes information on hepatitis prevention, screening, treatment, and coordination of client care. It also includes guidance for administrators on how to add or improve hepatitis services.

Get the Quick Guide for Clinicians and Administrators


^ Return to Top

AIDS Institute Update: Two New Hepatitis C Educational Materials

Posted May 2014

In celebration of May Hepatitis Awareness Month and May 19 Hepatitis Testing Day, the AIDS Institute Viral Hepatitis Section is pleased to announce the availability of two new HCV education materials.

Hepatitis C Testing Card – This double sided card is aimed at increasing hepatitis C screening among persons at-risk for hepatitis C, including those born between 1945 and 1965. The card outlines who should be screened for hepatitis C and includes information on the hepatitis C screening methods and test result interpretations.

Hepatitis C Counseling Message Pads – This new counseling message material is designed for persons performing HCV screening and counseling and to ensure appropriate counseling messages are delivered based on the screening test result. This material was developed in collaboration with the New York City Department of Health and Mental Hygiene.

Both materials are available to be ordered in English and Spanish. All materials are available free-of-charge through the NYSDOH Distribution Center.

Click here to download a special order form.


^ Return to Top

NYSDOH Update: Amended Health Law Related to HIV Testing

Updated May 2014

Amended Health Law related to HIV Testing – Please click here to download a letter from Dr. Nirav Shah, former NYS Commissioner of Health, describing changes to Public Health Law Section 2781 enacted to further increase HIV testing in the State and promote linkage and retention in care for HIV-positive persons.

For further information and guidance on HIV testing in New York State, including testing women in prenatal care, please see the New York State Department of Health website at:


^ Return to Top

Email Announcement Archives

Posted December 2009

The HIV Clinical Guidelines Program provides subscribers with email announcements of when new guidelines are posted and existing guidelines are updated.

hivguidelines email announcement archives

Subscribe to hivguidelines email announcements


^ Return to Top

Hot Topics Archive

Please visit the Hot Topics Archive page.

^ Return to Top